Catalyst Pharmaceuticals, Inc. (CPRX) Earnings History
Elite Compounder22 years of earnings data (2004–2025) · 5-year EPS CAGR exceeds 18% — top-tier earnings quality
Loading earnings history...
Catalyst Pharmaceuticals, Inc. (CPRX) Earnings Overview
As of June 22, 2026, Catalyst Pharmaceuticals, Inc. (CPRX) reported trailing twelve-month net income of $221M, reflecting +28.2% year-over-year growth. The company earned $1.74 per diluted share over the past four quarters, with a net profit margin of 36.4%.
Looking at the long-term picture, CPRX's 5-year EPS compound annual growth rate (CAGR) stands at +18.8%, indicating exceptional earnings growth. The company achieved its highest annual net income of $214M in fiscal 2025, representing a new all-time high.
Catalyst Pharmaceuticals, Inc. maintains industry-leading profitability with a gross margin of 85.2%, operating margin of 43.8%, and net margin of 36.4%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), ACAD ($376M net income, 36.5% margin), CPRX has outperformed on profitability metrics. Compare CPRX vs RARE →
CPRX Earnings vs Peers
Earnings metrics vs comparable public companies
CPRX Historical Earnings Data (2004–2025)
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $214M | +30.8% | $258M | $1.68 | 36.4% | 43.8% |
| 2024 | $164M | +129.5% | $195M | $1.31 | 33.3% | 39.7% |
| 2023 | $71M | -14.0% | $87M | $0.63 | 17.9% | 21.8% |
| 2022 | $83M | +110.4% | $102M | $0.75 | 38.8% | 47.5% |
| 2021 | $39M | -47.3% | $52M | $0.37 | 28.0% | 37.2% |
| 2020 | $75M | +135.2% | $41M | $0.71 | 63.0% | 34.7% |
| 2019 | $32M | +193.7% | $32M | $0.30 | 31.2% | 31.1% |
| 2018 | -$34M | -84.7% | -$35M | $-0.33 | -6800.7% | -7059.0% |
| 2017 | -$18M | -1.9% | -$19M | $-0.21 | - | - |
| 2016 | -$18M | +10.7% | -$19M | $-0.22 | - | - |
| 2015 | -$20M | -30.5% | -$20M | $-0.25 | - | - |
| 2014 | -$16M | -27.6% | -$15M | $-0.24 | - | - |
| 2013 | -$12M | -198.2% | -$10M | $-0.27 | - | - |
| 2012 | -$4M | +36.2% | -$5M | $-0.14 | - | - |
| 2011 | -$6M | -59.5% | -$6M | $-0.29 | - | - |
| 2010 | -$4M | +44.7% | -$4M | $-0.22 | -819.4% | -823.0% |
| 2009 | -$7M | +31.5% | -$7M | $-0.48 | - | - |
| 2008 | -$11M | -155.2% | -$11M | $-0.81 | - | - |
| 2007 | -$4M | -51.7% | -$5M | $-0.33 | - | - |
| 2006 | -$3M | -51.2% | -$3M | $-0.36 | - | - |
| 2005 | -$2M | -234.4% | -$2M | $-0.29 | - | - |
| 2004 | $-539,820 | - | $-542,958 | $-0.18 | - | - |
Download Data
Export CPRX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
22+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CPRX — Frequently Asked Questions
Quick answers to the most common questions about buying CPRX stock.
What is CPRX earnings per share (EPS)?
CPRX trailing twelve-month (TTM) diluted EPS is $1.74, reflecting +28.2% year-over-year growth. The 5-year EPS CAGR is +18.8%. Complete EPS history from 2004 to 2025 is available in the table on this page.
What is Catalyst Pharmaceuticals, Inc.'s net income?
Catalyst Pharmaceuticals, Inc. (CPRX) trailing twelve-month net income is $221M as of 2025. Earnings grew +28.2% year-over-year. Catalyst Pharmaceuticals, Inc. has been profitable for 7 consecutive years.
Is CPRX profitable?
Yes, CPRX is profitable with a TTM net income of $221M and a net profit margin of +36.4%. Catalyst Pharmaceuticals, Inc. has generated profits for 7 consecutive years.
What is CPRX's earnings growth rate?
CPRX compound annual EPS growth rates (CAGR): 1-Year: +28.2%, 3-Year: +30.8%, 5-Year: +18.8%, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2004 to 2025.
What are CPRX's profit margins?
Catalyst Pharmaceuticals, Inc. net profit margin is +36.4%, operating margin is +43.8%, and gross margin is +85.2%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +25.5%.
Is CPRX growing earnings?
Yes, CPRX earnings are accelerating — EPS growth of +28.2% exceeds the 5-year CAGR of +18.8%. TTM net income reached $221M. Earnings momentum is strengthening.
What was CPRX's best earnings year?
Catalyst Pharmaceuticals, Inc.'s highest annual net income on record is $214M, achieved in fiscal year 2025. Earnings history on this page spans 2004 to 2025 and includes all annual and quarterly figures.
What were CPRX's earnings last quarter?
CPRX's most recent reported quarter was Q1 2026. Net income was $64M with diluted EPS of $0.50. For a full breakdown of all quarters, see the quarterly earnings table on this page.